What is HC Wainwright’s Forecast for RMTI Q1 Earnings?

Rockwell Medical, Inc. (NASDAQ:RMTI) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Rockwell Medical in a note issued to investors on Monday, March 30th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.00 target price on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.01 EPS, Q4 2027 earnings at $0.02 EPS and FY2027 earnings at $0.04 EPS.

A number of other research firms have also weighed in on RMTI. Wall Street Zen raised shares of Rockwell Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rockwell Medical in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Rockwell Medical presently has an average rating of “Hold” and a consensus target price of $2.00.

Rockwell Medical Price Performance

RMTI opened at $0.89 on Tuesday. Rockwell Medical has a 1 year low of $0.78 and a 1 year high of $2.10. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.98 and a quick ratio of 3.63. The company has a market capitalization of $35.20 million, a price-to-earnings ratio of -5.95 and a beta of 1.71. The firm’s fifty day moving average price is $1.00 and its two-hundred day moving average price is $1.03.

Rockwell Medical (NASDAQ:RMTI) last announced its earnings results on Thursday, March 26th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.05). The company had revenue of $18.35 million for the quarter, compared to analysts’ expectations of $18.58 million. Rockwell Medical had a negative net margin of 7.67% and a negative return on equity of 15.64%.

Hedge Funds Weigh In On Rockwell Medical

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Panagora Asset Management Inc. bought a new stake in shares of Rockwell Medical in the 2nd quarter worth approximately $41,000. XTX Topco Ltd increased its holdings in Rockwell Medical by 286.5% in the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after acquiring an additional 46,029 shares during the last quarter. Jane Street Group LLC bought a new stake in Rockwell Medical in the 4th quarter valued at about $84,000. GSA Capital Partners LLP lifted its holdings in Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after purchasing an additional 141,672 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after purchasing an additional 41,668 shares during the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.